Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

Carl Jannes Neuse, Christoph Schliemann, Cyrus Khandanpour, Georg Lenz, Irene Ghobrial, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7493.

https://doi.org/10.1182/blood-2024-210454

Published: 2024

Journal Articles

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2024-198763

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Blood (2024) 144 (Supplement 1): 4759.

https://doi.org/10.1182/blood-2024-202467

Published: 2024

Journal Articles

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppusamy, Robert Autry, Lanying Wei, Kaiyan Sun, Helal Mohammed Mohammed Ahmed, Axel Künstner, Hauke Busch, Heiko Müller, Stephan Hutter, Gregor Hoermann, Longlong Liu, Xiaoqing Xie, Yahya Al-Matary, Subbaiah Chary Nimmagadda, Fiorella Charles Cano, Michael Heuser, Felicitas Thol, Gudrun Göhring, Doris Steinemann, Jürgen Thomale, Theo Leitner, Anja Fischer, Roland Rad, Christoph Röllig, Heidi Altmann, Desiree Kunadt, Wolfgang E. Berdel, Jana Hüve, Felix Neumann, Jürgen Klingauf, Virginie Calderon, Bertram Opalka, Ulrich Dührsen, Frank Rosenbauer, Martin Dugas, Julian Varghese, Hans Christian Reinhardt, Nikolas von Bubnoff, Tarik Möröy, Georg Lenz, Aarif M. N. Batcha, Marianna Giorgi, Murugan Selvam, Eunice Wang, Shannon K. McWeeney, Jeffrey W. Tyner, Friedrich Stölzel, Matthias Mann, Ashok Kumar Jayavelu, Cyrus Khandanpour

Blood (2023) 142 (25): 2175–2191.

https://doi.org/10.1182/blood.2022015752

Published: 2023

Includes: Supplemental data

Journal Articles

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Paulina Marie Budde, Helal Ahmed, Todd Covey, Cecile Krejsa, Wayne Rothbaum, Nikolas Von Bubnoff, Cyrus Khandanpour

Blood (2023) 142 (Supplement 1): 2782.

https://doi.org/10.1182/blood-2023-174895

Published: 2023

Journal Articles

Liquid Biopsy Enhances Diagnostic Workup of Hereditary Alpha-Tryptasemia (HaT) and Systemic Mastocytosis (SM) in Patients with Mast Cell-Mediated Symptoms and Elevated Basal Tryptase Levels

Daniel Koch, Hannah Stocker, Friederike Wortmann, Franziska Axt, Cyrus Khandanpour, Eva Dazert, Christian Sina, Dagmar von Bubnoff, Nikolas Von Bubnoff

Blood (2023) 142 (Supplement 1): 2546.

https://doi.org/10.1182/blood-2023-188962

Published: 2023

Journal Articles

Virtual Reality-Assisted Exercise Therapy during Inpatient Treatment after Intensive Chemotherapy for Acute Myeloid Leukemia (AML) and after Autologous or Allogeneic Stem Cell Transplantation

Friederike Wortmann, Philipp Koch, Cyrus Khandanpour, Nikolas Von Bubnoff

Blood (2023) 142 (Supplement 1): 5091.

https://doi.org/10.1182/blood-2023-174677

Published: 2023

Journal Articles

Mutational Changes in Solid Cancer Cells Induce DNA Damage Repair Deficiency in Hematopoietic Cells Leading to a Distinct Spectrum of Clonal Hematopoiesis Independent from Age-Related Clonal Hematopoiesis

Theo Leitner, Axel Künstner, Michael Kohl, Tobias Barmwater, Helal Mohammed Ahmed, Almuth Caliebe, Eva Dazert-Klebsattel, Anke Fähnrich, Stephanie Fliedner, Niklas Gebauer, Malte Spielmann, Jutta Kirfel, Verena-Wilbeth Sailer, Lorenz Bastian, Nikolas Von Bubnoff, Hauke Busch, Cyrus Khandanpour

Blood (2023) 142 (Supplement 1): 5605.

https://doi.org/10.1182/blood-2023-184994

Published: 2023

Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Blood (2023) 141 (14): 1685–1690.

https://doi.org/10.1182/blood.2022017789

Published: 2023

Includes: Supplemental data

Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Blood (2021) 138 (Supplement 1): 463.

https://doi.org/10.1182/blood-2021-145097

Published: 2021

Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Blood (2021) 138 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2021-146459

Published: 2021

Journal Articles

Leukaemia Cells Induced Metabolic Alterations in AML Associated Mesenchymal Stem Cells Via Notch Signalling

Helal Mohammed Mohammed Ahmed Noman, Yahya Saleh Al-Matary, Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Longlong Liu, Lanying Wei, Daria Frank, Georg Lenz, Cyrus Khandanpour

Blood (2021) 138 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2021-144468

Published: 2021

Journal Articles

Targeting PI3K-AKT-mTOR Signaling in Multiple Myeloma Mesenchymal Stem Cells Mediates Antiproliferative Effect on Myeloma Cells

Luca Heinmann, Helal Mohammed Mohammed Ahmed Noman, Klara Möllers, Subbaiah Chary Nimmagadda, Kaiyan Sun, Daria Frank, Hanna Korab, Lanying Wei, Anja Baumann, Alexandra Poos, Marc-Steffen Raab, Georg Lenz, Cyrus Khandanpour

Blood (2021) 138 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2021-150413

Published: 2021

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-134177

Published: 2020

Journal Articles

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Marc S. Raab, MD, Nicola Giesen, MD, Christof Scheid, MD, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, MD, Cyrus Khandanpour, PD, MD, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, MD, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, MD, Katja Weisel, MD, Manik Chatterjee

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142600

Published: 2020

Journal Articles

GFI1b As a Novel Oncosuppressor in AML

Aniththa Thivakaran, M.Sc., Lacramioara Botezatu, PhD, Judith Maria Hoenes, M.Sc., Yahya Saleh Al-Matary, MSc, Nadine Olberding, B.Sc, Judith Schütte, PhD, Renata Köster, Bertram Opalka, PhD, Ulrich Dührsen, MD, Cyrus Khandanpour, MD

Blood (2016) 128 (22): 2717.

https://doi.org/10.1182/blood.V128.22.2717.2717

Published: 2016

Journal Articles

the Role of MSCs in the Development of Acute Myeloid Leukemia

Yahya Saleh Al-Matary, MSc, Lacramioara Botezatu, PhD, Robert Fernando Lams, Aniththa Thivakaran, MSc, Renata Köster, Judith Schütte, PhD, Ulrich Dührsen, MD, Bertram Opalka, PhD, Cyrus Khandanpour, MD

Blood (2016) 128 (22): 2669.

https://doi.org/10.1182/blood.V128.22.2669.2669

Published: 2016

Journal Articles

From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation

Tarik Möröy, Lothar Vassen, Brian Wilkes, Cyrus Khandanpour

Blood (2015) 126 (24): 2561–2569.

https://doi.org/10.1182/blood-2015-06-655043

Published: 2015

NARROW

Evaluation of Urine cfDNA for Non-Invasive Genomic Characterization in Multiple Myeloma: A Comparative Study with Serum and Bone Marrow Samples

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Liquid Biopsy Enhances Diagnostic Workup of Hereditary Alpha-Tryptasemia (HaT) and Systemic Mastocytosis (SM) in Patients with Mast Cell-Mediated Symptoms and Elevated Basal Tryptase Levels

Virtual Reality-Assisted Exercise Therapy during Inpatient Treatment after Intensive Chemotherapy for Acute Myeloid Leukemia (AML) and after Autologous or Allogeneic Stem Cell Transplantation

Mutational Changes in Solid Cancer Cells Induce DNA Damage Repair Deficiency in Hematopoietic Cells Leading to a Distinct Spectrum of Clonal Hematopoiesis Independent from Age-Related Clonal Hematopoiesis

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Leukaemia Cells Induced Metabolic Alterations in AML Associated Mesenchymal Stem Cells Via Notch Signalling

Targeting PI3K-AKT-mTOR Signaling in Multiple Myeloma Mesenchymal Stem Cells Mediates Antiproliferative Effect on Myeloma Cells

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

GFI1b As a Novel Oncosuppressor in AML

the Role of MSCs in the Development of Acute Myeloid Leukemia

From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only